A growing number of employers are considering covering the blockbuster weight-loss drugs, several surveys show. Workers will learn whether they’ll gain such coverage for the coming year during open enrollment,

Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance plans, a new survey shows.

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions of dollars, according to a new report by the Congressional Budget Office (CBO).

That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a growing number say they’re open to covering GLP-1 drugs, they’re still in the minority. Some 62% of the firms surveyed said they are “not likely” to begin coverage in the coming year.

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the medicine must stop.

When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies cover the

Compounding pharmacies are suing the Food and Drug Administration so they can keep making imitation versions of popular—and lucrative—tirzepatide drugs, namely knockoffs of Mounjaro for diabetes and Zepbound for weight loss.

With the shortage over, compounding pharmacies are no longer allowed to produce the popular weight loss drugs.